Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

T.P. Hughes, A Hochhaus, H.M. Kantarjian, F. Cervantes, F. Guilhot, D. Niederwieser, P.D. le Coutre, G. Rosti, G.J. Ossenkoppele, C. Lobo, H. Shibayama, X.L. Fan, H.D. Menssen, C. Kemp, R.A. Larson, G. Saglio

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1204-1211
JournalHaematologica
Volume99
Issue number7
DOIs
Publication statusPublished - 2014

Cite this

Hughes, T.P. ; Hochhaus, A ; Kantarjian, H.M. ; Cervantes, F. ; Guilhot, F. ; Niederwieser, D. ; le Coutre, P.D. ; Rosti, G. ; Ossenkoppele, G.J. ; Lobo, C. ; Shibayama, H. ; Fan, X.L. ; Menssen, H.D. ; Kemp, C. ; Larson, R.A. ; Saglio, G. / Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. In: Haematologica. 2014 ; Vol. 99, No. 7. pp. 1204-1211.
@article{707ea2d8d71f465d99224bd40eeab55f,
title = "Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily",
author = "T.P. Hughes and A Hochhaus and H.M. Kantarjian and F. Cervantes and F. Guilhot and D. Niederwieser and {le Coutre}, P.D. and G. Rosti and G.J. Ossenkoppele and C. Lobo and H. Shibayama and X.L. Fan and H.D. Menssen and C. Kemp and R.A. Larson and G. Saglio",
year = "2014",
doi = "10.3324/haematol.2013.091272",
language = "Undefined/Unknown",
volume = "99",
pages = "1204--1211",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

Hughes, TP, Hochhaus, A, Kantarjian, HM, Cervantes, F, Guilhot, F, Niederwieser, D, le Coutre, PD, Rosti, G, Ossenkoppele, GJ, Lobo, C, Shibayama, H, Fan, XL, Menssen, HD, Kemp, C, Larson, RA & Saglio, G 2014, 'Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily' Haematologica, vol. 99, no. 7, pp. 1204-1211. https://doi.org/10.3324/haematol.2013.091272

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. / Hughes, T.P.; Hochhaus, A; Kantarjian, H.M.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; le Coutre, P.D.; Rosti, G.; Ossenkoppele, G.J.; Lobo, C.; Shibayama, H.; Fan, X.L.; Menssen, H.D.; Kemp, C.; Larson, R.A.; Saglio, G.

In: Haematologica, Vol. 99, No. 7, 2014, p. 1204-1211.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

AU - Hughes, T.P.

AU - Hochhaus, A

AU - Kantarjian, H.M.

AU - Cervantes, F.

AU - Guilhot, F.

AU - Niederwieser, D.

AU - le Coutre, P.D.

AU - Rosti, G.

AU - Ossenkoppele, G.J.

AU - Lobo, C.

AU - Shibayama, H.

AU - Fan, X.L.

AU - Menssen, H.D.

AU - Kemp, C.

AU - Larson, R.A.

AU - Saglio, G.

PY - 2014

Y1 - 2014

U2 - 10.3324/haematol.2013.091272

DO - 10.3324/haematol.2013.091272

M3 - Article

VL - 99

SP - 1204

EP - 1211

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -